Search PubMed⌕ Search

Biomedical subjects

C Gisselbrecht

Publications and source records attributed to C Gisselbrecht.

At least 163 records · Page 9Linked to original sources
PubMed1989

[Comparison of the antiemetic effectiveness of high-dose corticosteroids with synacthene in nausea induced by chemotherapy: results of a randomized study].

One hundred two patients submitted to intensive chemotherapy were included in a randomized study with cross over comparing for the second course two anti-emetics: tetracosactide (D1: 3 mg, D2 and D3: 2 mg/d) and methylprednisolone (D1: 240 mg, D2 and D3: 160 mg/d). Most patients presented with malignant lymphoma. All patients experienced nausea and emesis during first course of chemotherapy. Results were similar in both groups, respectively for tetracosactide and methylprednisolone: no nausea 37 versus 40%, less than 3 emesis 69% versus 73%. Secondary effects were observed in 5 and 8% of cases. Tetracosactide with a schedule of 7 mg for 3 days gives the same results than methylprednisolone 560 mg for 3 days in chemotherapy induced nausea and emesis prevention.

Adolescent↗
PubMed1988

[The place of bone marrow autografts in the treatment of Hodgkin's and non-Hodgkin's lymphoma].

The therapeutic approach to relapses in aggressive non-Hodgkin's lymphoma has been changed by high dose chemotherapy and autologous bone marrow graft. In the absence of dramatic improvement following the conditioning regimen, such a procedure should be reserved for patients still sensitive to salvage therapy. Up to 40%-50% of these selected cases can expect prolonged disease-free survival. Autologous bone marrow graft in first remission should only be considered in poor prognosis patients in a carefully randomized study. In Hodgkin's disease, relapses and patients in partial remission after MOPP and ABVD treatment are potential candidates for autologous bone marrow graft. Preliminary results indicate a disease-free survival up to 50%.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1988

Radiation-induced lung injuries: a survey by computed tomography and pulmonary function tests in 18 cases of Hodgkin's disease.

Eighteen patients with Hodgkin's disease received chemotherapy and 40 Gy mantle-field irradiation. Radiation-induced lung injuries were studied 5 times during one year for each patient by chest x-ray, CT examination of the thorax and pulmonary function tests. Homogeneous and inhomogeneous densities developed within the radiations ports. They were more often and more easily detected by CT than by chest x-ray (39% vs 11% at the end of the irradiation). CT changes suggested that homogeneous lung density increase and lung nodules corresponded to the radiation pneumonitis phase, also that linear aspects and/or lung condensation aspects corresponded to irradiation-induced lung fibrosis. The displacement of the vessels and the fissures were seen more precisely by CT than by chest x-ray. There was a highly significant correlation between the number of modified areas and the increase in the coefficient of retraction (p less than 0.001).

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1988

[Residual masses after chemotherapy of non-Hodgkin's lymphoma].

Among 149 patients treated for high grade non-Hodgkin's lymphoma, 22 post-therapy mediastinal and abdominal residual masses were observed (14.7%). In 12 cases, initial histology was malignant lymphoma, diffuse large cell. The follow-up of these patients was similar to those without residual masses. Magnetic resonance imaging may be helpful in distinguishing viable tissue from fibrotic tissue.

Fibrosis↗
PubMed1987

[Low-grade non-Hodgkin's lymphoma in the adult: new therapeutic approaches].

Treatment of disseminated low grade non-Hodgkin's lymphomas (NHL) remains unsolved. Despite an initial high remission rate (50%-70%) with chemotherapy, relapses occur and only 20 to 40% of patients are expected to be free of disease after 10 years. From 1981 to 1984, 113 low grade NHL were studied in order to determine factors influencing survival without progression. In a randomized trial, patients received either PCOP combination or PACOP for 6 months followed by chlorambucil or CVP for 12 months. Histological distribution was: follicular small cleaved cells 70 patients, follicular mixed 31 patients, small cells CLL type 12 patients. Stage distribution was: stage IV 88 patients with 74 bone marrow involvement, stage III 17 patients, stage II with bulky masses 8 patients. Complete response (CR) was observed in 49 patients at the end of treatment. Among the ten variables studied, only stage and the number of sites involved had a significant effect on the probability of achieving CR. Only CR significantly affected the freedom from progression (P less than 0.01). Median survival after progression was 21 months. Recently, alpha recombinant interferon has been proposed as treatment for low grade NHL. Cumulative results from the literature give a response rate of 42% on 139 patients. The response rate was higher in follicular NHL than in the CLL type, and response did not clearly correlate with dose. The CR rate was low (less than 20%) and relapses occurred after stopping therapy. Combined use of interferon and chemotherapy is proposed for future clinical trials.

Adult↗
PubMed1987

Peripheral T cell lymphoma following angioimmunoblastic lymphadenopathy.

We report 5 cases of peripheral T cell lymphoma (PTCL) which initially presented as angioimmunoblastic lymphadenopathy (AIL). In 4 cases, the delay between the 2 phases was less than 1 year, and 3 patients were under corticosteroid therapy when the second biopsy was performed. Clinical and biological features were very similar during the 2 phases. The initial disease was morphologically characterized by a high cellular pleomorphism with immunoblasts, plasma cells, eosinophils and lymphoid cells of various size with abundant venules; this pleomorphism then regressed, emphasizing the T cell nature of the lymphoma, as proven by immunological staining with monoclonal antibodies raised against T cell subpopulations. In 4 cases, T cell proliferation bore T helper (CD4) and T cytotoxic/suppressor (CD8) antigens and, in 1 case only, CD4 antigen. The entity of AIL and the role of corticosteroid therapy is discussed; the short interval between the 2 diagnose suggests that T cell proliferation was present initially, but was masked by reactive B lymphocytes.

Adult↗
PubMed1987

[Therapy of acute leukemia in the adult. Role of anthracyclines].

Anthracyclines chemotherapy has changed the outcome of adult acute leukemia. Daunomycin, Adriamycin and Zorubicine are the three main analog derivatives. In adult ALL, in randomized study, anthracyclines in induction regimen improve significantly the remission rate up to 80%. In AML, combination chemotherapy of Ara-C and anthracyclines is the standard induction regimen. In randomized study, Daunomycin has the same activity than adriamycin at the same dose with less toxicity. Comparison of Daunomycin: 60 mg/m2 X 3 d with Zorubicin: 120 mg/m2 X 3 d shows the same activity in association with Ara-C with less toxicity. In protocol 01 AM 81, Zorubicin has been used at the dose of 200 mg/m2 X 4 d in association with Ara-C: 200 mg/m2 X 5 d. 444 patients has been included in the study. The complete remission rate is 83% with a mortality rate of 7% and only 11% failure. Zorubicin allows intensification of induction regimen with similar or less toxicity than conventionnal regimens.

Adult↗
PubMed1987

Long duration of response with vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy in metastatic breast cancer: a pilot phase II study.

A total of 39 women with metastatic breast cancer entered a pilot phase II study of the vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy. Most of them had received previous chemotherapy [including doxorubicin (27 patients)] for their primary or metastatic disease. The VMMc drugs were given at usual doses. Hematologic side effects were the most serious, leading mainly to leukopenia (five episodes of infection were successfully treated). A 33% partial response rate was obtained (95% confidence limits, 18%-48%), with a median duration (not yet reached) of greater than 510 days (range, 150-720) for the overall population. The median for pretreated patients was greater than 420 days (range, 150-720) which compares favorably with those previously reported in similar patients treated by mitomycin and vindesine or vinblastine.

Adult↗
PubMed1987

Role of CT in the study of recurrences of Hodgkin's disease on the chest wall. Report on 12 cases.

Twelve cases of recurrences of Hodgkin's disease on the chest wall, associated with three breast lesions and three diaphragmatic lesions, were studied by computed tomography (CT). Although the chest radiographs of all the patients were abnormal, CT was more accurate than clinical and other radiological examinations in delineating the lesions of the chest wall and in studying the extension of the relapse. Muscle enlargement was present in all cases. In seven cases osseous lesions and in seven cases pleural effusion or subpleural plaques were found. Chest wall recurrences were associated with other thoracic or abdominal lesions in 75% of the cases. Recurrences to the chest wall occur late (mean 6.3 years) in the evolution of Hodgkin's disease. They developed during the first relapse in 67% of the cases and during the second to the fourth relapse in 33% of the cases. CT is useful for the screening of lesions for which the outcome is bad. Only in four cases patients were without any evidence of disease after treatment.

Adult↗
PubMed1986

[Early post-radiation pericardial changes in Hodgkin's disease. Value of x-ray computed tomography].

Eighteen patients with mediastinal Hodgkin's disease treated with chemotherapy first, then irradiation were investigated during 1 year by means of 5 CT and radiological examinations of the chest. Four months after irradiation pericardial thickening was detected in 60 p. cent of the patients. The authors underline the high frequency, early occurrence and usually spontaneous resolution of radiation-related pericarditis without clinical or radiological signs.

Adolescent↗
PubMed1986

Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach.

A combination of 5-FU (600 mg/m2 on Days 1 and 8), doxorubicin (40 mg/m2 on Day 1), and cisplatin (75 mg/m2 on Day 1) has been used for treatment of 31 patients with advanced measurable adenocarcinoma of the lung and 35 with gastric cancer. The regimen was given every 4 weeks until disease progression to patients who had not received prior chemotherapy. One complete response occurred in the lung cancer group. Ten of the gastric cancer patients (29%) had partial responses. The median duration of response was 5.5 months and the median survival in responding patients was 10.8 months. Toxicity of the regimen was moderate. We conclude that this combination offers no particular advantages over previously described treatments for these diseases.

Adenocarcinoma↗